Program
vepdegestrant
Also written as “ARV-471”, “Vepdegestrant” and “[phenyl-14C]ARV-471”.
Its studies are mostly in Breast Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 176 open or running | phase 3since Nov 16, 2022 | Jul 14, 2022 | Dec 4, 2026phase 1 · NCT07231991 |
| Arvinas Estrogen Receptor | 20 open or running | phase 2since Aug 27, 2019 | Aug 27, 2019 | none ahead |
| Arvinas | 10 open or running | phase 2since Sep 7, 2022 | Sep 7, 2022 | none ahead |
Also a collaborator on its studies: carrick-therapeutics-limited.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Aug 27, 2019.
- Oct 5, 2022Phase 2 study in Breast NeoplasmsPfizer · NCT05573555 · 20 enrolled · United States, Canada, Italy and more
- Nov 16, 2022Phase 3 study in Breast NeoplasmsPfizer · NCT05654623 · 624 enrolled · United States, Argentina, Australia and more
- Dec 7, 20222 phase 1 studies in HealthyPfizer · NCT05652660, NCT05673889
- Jan 17, 2023Phase 1 study in Breast NeoplasmsPfizer · NCT05732428 · 9 enrolled · China
- May 25, 2023Phase 3 study in Breast NeoplasmsPfizer · NCT05909397 · 59 enrolled · United States, Australia, Brazil and more
- Jun 8, 2023Phase 1 study in HealthyPfizer · NCT05930925 · 12 enrolled · United States
- Aug 15, 2023Phase 1 study in Healthy ParticipantsPfizer · NCT06005688 · 12 enrolled · Belgium
- Oct 16, 2023Phase 2 study in Breast NeoplasmsPfizer · NCT06125522 · 11 enrolled · United States, Belgium, France and more
- Dec 13, 2023Phase 2 study in Breast NeoplasmsPfizer · NCT06206837 · 71 enrolled · United States, Belgium, Canada and more
- Feb 5, 20242 phase 1 studiesPfizer · NCT06256510, NCT06275841
- Mar 28, 2025Phase 1 study in Healthy ParticipantsPfizer · NCT06911788 · 10 enrolled · Netherlands
- Nov 13, 2025Phase 1 study in Healthy ParticipantsPfizer · NCT07231991 · 24 planned · United States
- Oct 27, 2026Phase 2 study terminatedStudy stoppedNCT05573555 · “Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. The decision was not related to…”
- Oct 27, 2026Phase 2 study terminatedStudy stoppedNCT06125522 · “Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. The decision was not related to …”
Ahead
- Dec 4, 2026Primary completion: phase 1 study in Healthy ParticipantsPfizer · NCT07231991
- Dec 30, 2026Primary completion: phase 3 study in Breast NeoplasmsPfizer · NCT05909397
- Mar 24, 2027Primary completion: phase 2 study in Breast NeoplasmsPfizer · NCT05548127
TargetBeta
“An orally available hetero-bifunctional molecule and selective estrogen receptor (ER) alpha-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, ”NCIt, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07231991Healthy Participants · United States | 1 | Recruiting | Pfizer | Dec 4, 2026 | 24 |
| NCT06911788Healthy Participants · Netherlands | 1 | Completed | Pfizer | May 23, 2025 | 10 |
| NCT06275841Healthy · United States | 1 | Completed | Pfizer | May 3, 2024 | 12 |
| NCT06256510Healthy Participants · Belgium | 1 | Completed | Pfizer | Apr 16, 2024 | 15 |
| NCT06206837Breast Neoplasms · United States, Belgium, Canada and more | 2 | Active, not recruiting | Pfizer | Sep 5, 2025 | 71 |
| NCT06125522Breast Neoplasms · United States, Belgium, France and more | 2 | Terminated | Pfizer | Sep 10, 2026 | 11 |
| NCT06005688Healthy Participants · Belgium | 1 | Completed | Pfizer | Oct 11, 2023 | 12 |
| NCT05930925Healthy · United States | 1 | Completed | Pfizer | Jul 27, 2023 | 12 |
| NCT05909397Breast Neoplasms · United States, Australia, Brazil and more | 3 | Active, not recruiting | Pfizer | Dec 30, 2026 | 59 |
| NCT05732428Breast Neoplasms · China | 1 | Completed | Pfizer | Mar 29, 2024 | 9 |
| NCT05673889Healthy · Belgium | 1 | Completed | Pfizer | Mar 15, 2023 | 24 |
| NCT05652660Healthy · United States | 1 | Completed | Pfizer | Feb 9, 2023 | 12 |
| NCT05654623Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Jan 31, 2025 | 624 |
| NCT05573555Breast Neoplasms · United States, Canada, Italy and more | 2 | Terminated | Pfizer | Oct 6, 2026 | 20 |
| NCT05538312Healthy · Belgium | 1 | Completed | Pfizer | Apr 24, 2023 | 12 |
| NCT05549505Breast Neoplasms · United States, Georgia, Germany and more | 2 | Completed | Arvinas | Jul 13, 2024 | 152 |
| NCT05548127Breast Neoplasms · United States, Canada, Italy and more | 2 | Active, not recruiting | Pfizer | Mar 24, 2027 | 37 |
| NCT05501769Breast Neoplasms · United States, Spain | 1 | Completed | Arvinas Estrogen Receptor | Jul 3, 2024 | 32 |
| NCT05463952Breast Neoplasms · Japan | 1 | Active, not recruiting | Pfizer | May 4, 2023 | 6 |
| NCT04072952Breast Neoplasms · United States | 2 | Completed | Arvinas Estrogen Receptor | Sep 13, 2024 | 219 |
How it is read
Names in the registry
- “ARV-471”, 7 entries
- “vepdegestrant”, 6 entries
- “Vepdegestrant”, 4 entries
- “[phenyl-14C]ARV-471”, 1 entry
- “[oxoisoindolin-14C]ARV-471”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 11 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.